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http://dx.doi.org/10.1016/j.ccr.2014.05.005SUMMARYFunctional heterogeneity within tumors presents a significant therapeutic challenge. Here we show that
quiescent, therapy-resistant Sox2+ cells propagate sonic hedgehog subgroup medulloblastoma by a mech-
anism thatmirrors a neurogenic program. Rare Sox2+ cells produce rapidly cycling doublecortin+ progenitors
that, together with their postmitotic progeny expressing NeuN, comprise tumor bulk. Sox2+ cells are enriched
following anti-mitotic chemotherapy and Smoothened inhibition, creating a reservoir for tumor regrowth.
Lineage traces from Sox2+ cells increase following treatment, suggesting that this population is responsible
for relapse. Targeting Sox2+ cells with the antineoplastic mithramycin abrogated tumor growth. Addressing
functional heterogeneity and eliminating Sox2+ cells presents a promising therapeutic paradigm for treat-
ment of sonic hedgehog subgroup medulloblastoma.INTRODUCTION
Medulloblastoma (MB) arises in the cerebellum and is the
most common malignant pediatric brain tumor. Aggressive yetSignificance
Cell populations enriched for their tumor-propagating ability h
tumor-propagating cells contribute to primary tumor growth is
Sox2 are mouse medulloblastoma-propagating cells (MPCs) in
strate that medulloblastoma growth parallels a developmental
resistant to antimitotic and Shh-targeted therapy and are likely
ture is predictive of poor outcome in SHH-medulloblastoma p
with the aureolic acid mithramycin, which may have therapeutnonspecific multimodal therapy has significantly improved MB
outcomes but leaves survivors with debilitating secondary
sequelae (Crawford et al., 2007). Cases of disease relapse are
almost uniformly fatal (Zeltzer et al., 1999). It is essential toave been identified in many cancers, but whether and how
unknown. Herewe show that rare, quiescent cells expressing
allograft transplants and in situ primary tumors. We demon-
stem cell hierarchy and is driven by Sox2+ cells. MPCs were
responsible for disease relapse. Accordingly, a MPC signa-
atients. Tumor growth was stopped by targeting Sox2+ cells
ic potential for SHH-medulloblastoma.
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Quiescent Sox2+ Cells Drive Medulloblastomadefine the mechanism of tumor growth and relapse to develop
tailored therapies to selectively ablate cells responsible for
MB expansion and recurrence while sparing the developing
brain.
Medulloblastoma was named for its histological similarity to
the embryonic brain (Bailey and Cushing, 1925) and exhibits
significant intratumoral heterogeneity. The constituent MB cell
types heterogeneously express stem, astroglial, and neuronal
markers, with each population’s contribution to tumor expansion
unclear. Although both mouse and human MBs are functionally
heterogeneous for the ability to self-renew in tumor-propagating
cell assays, whether the transplantable cells drive primary tumor
growth and relapse in situ remains unresolved (Read et al., 2009;
Singh et al., 2004; Ward et al., 2009). Recently, the cancer stem
cell hypothesis was tested using genetic lineage tracing of pri-
mary tumors in mouse models of colon adenocarcinoma and
squamous skin cancer (Driessens et al., 2012; Schepers et al.,
2012). Both studies found that developmental hierarchies were
preserved in tumors that were dependent upon the proliferation
of stem-like cells for continued expansion. These results suggest
that the stem cell hierarchies inferred from transplantation
studies exist in primary cancers, but this remains unsubstanti-
ated (Meacham and Morrison, 2013).
Transient withdrawal from the cell cycle into a quiescent state
is a defining characteristic of many somatic stem cells, including
neural stem cells (Li and Clevers, 2010). Quiescent, self-renew-
ing cancer cells have been identified in several malignancies
(Guan et al., 2003; Holyoake et al., 1999; Roesch et al., 2010;
Saito et al., 2010) and are often resistant to conventional chemo-
therapy and radiation, thus acting as a reservoir for recurrence. A
prior study reported thatMB cells expressing the neural stem cell
marker nestin withdraw from the cell cycle in response to radia-
tion, although their tumor-propagating capacity was not defined
(Hambardzumyan et al., 2008). This study suggests that the self-
renewing MB population may be quiescent, but proliferative het-
erogeneity and the detailed definition of lineage relationships
between heterogeneous MB cell types and their links to self-
renewal were not explored.
Medulloblastomas comprise four clinically and molecularly
distinct subgroups (Northcott et al., 2012). Thirty percent of
MB diagnoses present aberrant sonic hedgehog (SHH) signaling
because of loss of function in negative regulators, including
PTCH1 and SUFU, activating mutations in positive transducers
such as SMO, and amplifications in transcriptional effectors
like GLI2 (Northcott et al., 2012). SHH pathway inhibitors are
entering MB clinical trials to define subgroup-specific therapy,
but laboratory and clinical reports of resistance suggest that
an insensitive cell type may be spared (Kool et al., 2014;
LoRusso et al., 2011; Rudin et al., 2009; Yauch et al., 2009).
Here we dissect SHH subgroup MB heterogeneity at the
cellular level to investigate the principles of tumor expansion
and their clinical implications.
RESULTS
Ptc Medulloblastoma Resembles a Dysregulated
Neurogenic System
We studied the irradiated Ptch1+/ (Ptc) mouse model of SHH
subgroup MB (Goodrich et al., 1997), where postnatal day34 Cancer Cell 26, 33–47, July 14, 2014 ª2014 Elsevier Inc.0 irradiation increases tumor incidence from 20% to more
than 80% (Pazzaglia et al., 2006). Characterization of these
tumors’ phenotypic heterogeneity by immunohistochemistry
revealed the ectopic expression of stem and progenitor markers
reminiscent of the developing cerebellum. Cells expressing the
neural stem cell markers Sox2 and nestin were relatively rare,
with Sox2+ cells comprising less than 5% of the tumor (Fig-
ure 1A; Figure S1A available online). The rarity of Sox2+ cells
was confirmed in a number of other Ptc tumor models (Fig-
ure S1B). Cells expressing glial-fibrillary acidic protein (GFAP)
were found throughout the tumor (Figure S1C). The neural
progenitor marker doublecortin (DCX) was expressed by
approximately 60% of all cells (Figure 1A). Neuronal nuclei
(NeuN), normally expressed by nascent and mature neurons,
was found in 30% of cells, exhibiting some overlap with DCX,
as occurs in cerebellar neurogenesis (Figure 1A; Figure S1D)
(Hatten and Roussel, 2011). Sox2+ cells are mutually exclusive
from DCX+ and NeuN+ cells (Figures S1E and S1F). Mature
markers of cerebellar neuronal subtypes, including granule neu-
rons, interneurons, and Purkinje cells, were not detectable
within the tumor, reflecting a lack of terminal differentiation in
this malignancy (Figures S1G–S1P).
Sox2-Expressing Cells Are Quiescent Compared with
Rapidly Cycling Tumor Bulk
In many tissues, the cells with the greatest capacity for growth
are cycling slowly. To address proliferative heterogeneity in Ptc
MB, we detected Ki67 using flow cytometry of primary tumor
cells and found that most cells and the majority of DCX+ cells
were Ki67+ and, therefore, cycling. In contrast, Sox2+ cells
were largely Ki67 and, thus, could be a quiescent population
(Figure 1B). We then used a chronic thymidine analog label-
chase experiment as a functional assay to define tumor-prolifer-
ative dynamics. Five-week-old mice were administered drinking
water containing 5-ethynyl-20deoxyuridine (EdU) for 7 days and
sacrificed on successive days of the label and a 21-day chase
(Figure 1C). As a whole, tumors rapidly acquired and diluted
the EdU label, confirming a high degree of cell proliferation and
turnover (Figure 1D). At the end of 7 days, nearly 90% of tumor
cells were EdU+. With a delay relative to all tumor cells, NeuN+
cells also labeled extensively but did not retain EdU throughout
the chase period because of label dilution or cell loss (Figures
1D and 1E). Interestingly, Sox2+ cells acquired EdUmore slowly,
labeled to a lesser extent, and maintained the label longer
throughout the chase, all of which are characteristic of a quies-
cent cell population (Figures 1D and 1E). To determine whether
Sox2+ cells cycle continually, mice were subjected to a pulse-
chase-pulse regimen of 7 days of 5-chloro-20-deoxyuridine
(CldU) drinking water, 2-week chase, and 7 days of drinking
water containing 5-iodo-20-deoxyuridine (IdU) (Figure 1F). Slowly
cycling cells were marked with both CldU and IdU, having
retained the first label (CldU), and divided at least once during
the week of IdU labeling prior to sacrifice. Only rare cells
(<0.5%) were positive for both proliferative markers, but nearly
all double-labeled cells were Sox2+, confirming this population
to be continuously cycling slowly and not merely label retaining
(Figures 1G and 1H). Less than 10% of Sox2+ cells were double
labeled, having divided during the initial CldU pulse and again
during the 7 days prior to sacrifice.
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Figure 1. Sox2+ Ptc MB Cells Are Quiescent
(A) Representative images of PtcMB containing Sox2+ cells (<5%), DCX-expressing cells (60%), and NeuN-expressing cells (30%). DAPI is shown in white. Scale
bars, 25 mm.
(B) Frequency of Ki67 expression in primary tumor cells: all counts, DCX+ cells, and Sox2+ cells (n = 3, mean ± SEM, two-tailed unpaired t test).
(C) Experimental design for (D) and (E). 31-day-old Ptc mice were administered 0.82 mg/mL EdU drinking water for 7 days (experimental days 0-7), followed by a
21-day chase. Mice were sacrificed on the indicated days of label or chase.
(D) The frequency of all EdU+ cells as well as NeuN+ and Sox2+ cells that are also EdU+ was quantified from primary tumor sections throughout the labeling and
chase (n = 3 per group, mean ± SEM).
(E) Representative immunofluorescence images at the end of the chase (day 28). DAPI is shown in white. Scale bars, 14 mm.
(F) Experimental design for (G) and (H). 31-day-old Ptc mice were administered (0.74 mg/ml) CldU drinking water for 7 days, returned to normal drinking water for
2 weeks, and were then administered (1 mg/ml) IdU drinking water for 7 days. Mice were sacrificed at the end of the IdU labeling (day 28).
(G) A representative immunofluorescence image of a Sox2+ cell that retained the CldU label and acquired IdU. Scale bar, 14 mm.
(H) The frequency of Sox2-expressing cells within the CldU+ IdU+ population at day 28 (n = 3 per group, mean ± SEM, two-tailed unpaired t test).
See also Figure S1.
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Figure 2. NeuN+ Cells Are the Short-Lived,
Differentiated Progeny of Cycling DCX+
Cells
(A) Experimental design for (B–D). Ptc mice were
injected with 30 mg/kg EdU and sacrificed at
successive time points thereafter.
(B) The frequency of all EdU+ cells as well as
DCX+, NeuN+, and Sox2+ cells that were also
EdU+ was quantified in primary tumor sections at
each postinjection time point (n = 3 per group,
mean ± SEM).
(C) Representative immunofluorescence images
of DCX and EdU at 3 hr and 14 days postinjection.
The arrowhead indicates a rare EdU+ label-
retaining cell. Scale bars, 20 mm.
(D) Representative immunofluorescence images
of NeuN and EdU at 3 hr and 3 days postinjection.
Scale bars, 20 mm.
(E) Representative image of activated caspase 3+
(AC3) NeuN+ cells (arrowhead). The frequency of
AC3 events in all cells, NeuN+ cells, and Sox2+
primary tumor cells is quantified (n = 3 [all], n = 3
[Sox2], n = 8 [NeuN], mean ± SEM, two-tailed
unpaired t test [NeuN versus all and NeuN versus
Sox2]). DAPI is shown inwhite. Scale bars, 14 mm.
(F) Representative image of TUNEL staining in
NeuN+ cells (arrowhead). The frequency of
TUNEL events in all, NeuN+ cells, and Sox2+ pri-
mary tumor cells is quantified (n = 3 per group,
mean ± SEM, two-tailed unpaired t test [NeuN
versus all and NeuN versus Sox]). DAPI is shown
in white. Scale bars, 14 mm.
See also Figure S2.
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NeuN+ cells were almost uniformly Ki67 (Figure S2), a finding
that was inconsistent with their EdU labeling kinetics. To address
this, we injected Ptcmice with a single dose of EdU to birthdate a
cohort of dividing cells and sacrificed the mice at successive
time points thereafter to follow the EdU marker in a lineage trace
(Figure 2A). Immediately after injection, the EdU label was found
almost exclusively in the DCX+ population, with only rare Sox2+
cells labeled (Figures 2B and 2C). Virtually no NeuN+ cells were
labeled at 3 hr postinjection. Thus, few cells in this population
were passing through S phase (Figures 2B and 2D). Indeed,
the EdU label was not detected in NeuN-expressing cells until
3 days postinjection, when the absolute number of labeled cells
and EdU+ DCX+ cells was decreasing (Figures 2B and 2D). This
suggests that NeuN+ cells inherit the EdU label from DCX+ cells
that differentiate and begin to express NeuN as they exit the cell
cycle, establishing a lineage relationship between these popula-
tions. Differentiated NeuN+ MB cells are the progeny of DCX+
progenitor-like tumor cells, produced in a pattern similar to the
one that occurs in cerebellar development (Hatten and Roussel,
2011). The frequency of labeled Sox2+ cells decreasedminimally
throughout the chase, consistent with their quiescent status
(Figure 2B).
As in the chronic EdU label-chase experiment, the frequency
of labeled NeuN+ cells dropped precipitously following their
peak labeling at chase day 3 (Figure 2B). A decrease in the fre-
quency of labeled cells in a population can be attributed to a
combination of label dilution through cell division, cell replace-
ment by newborn cells, and cell loss. Because NeuN+ cells are36 Cancer Cell 26, 33–47, July 14, 2014 ª2014 Elsevier Inc.Ki67 and do not exhibit linear labeling kinetics, we hypothe-
sized that cell loss is a principal cause of the decrease in the fre-
quency of EdU+ NeuN+ cells. We found that the levels of
apoptosis, as assessed by activated caspase 3 and TUNEL
staining, are significantly higher in NeuN+ cells when compared
to all tumor cells or Sox2+ cells (Figures 2E and 2F). Together,
these data confirm the slow-cycling longevity of Sox2+ cells
and suggest that NeuN+ cells, comprising nearly one third of
the tumor, are the short-lived, postmitotic progeny of the
DCX+-amplifying progenitor population.
Tumor-Propagating Cells Express Sox2
Many quiescent stem cell populations, including Sox2-express-
ing neural stem cells, exhibit greater self-renewal than
their proliferating progeny. To determine whether Sox2+ MB
cells self-renew in tumor-propagating cell assays, we crossed
Sox2-eGFP reporter mice to the Ptc MB model for functional
analysis, specifically marking Sox2+ cells with GFP (Figure S3).
Sox2-expressing cells were isolated as a discrete eGFPhigh pop-
ulation from primary tumors depleted of microglia, leukocytes,
and red blood cells (Figure 3A). On average, CD15/Lewis-x/
SSEA-1 marks 40% of Ptc tumor cells and can be used to enrich
cells with a tumor-propagating capacity (Read et al., 2009; Ward
et al., 2009).More than 80%of Sox2+ cells are CD15+, and Sox2+
cells comprise a minority (<10%) of the CD15+ population (Fig-
ures 3B and 3C). We initially measured self-renewal using an
in vitro colony-forming assay performed at limiting dilutions
and found that Sox2+ cells were significantly enriched for col-
ony-forming ability (Figure 3D). The current gold standard for
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Figure 3. Sox2+ MB Cells Are Tumor Propagating
(A) Representative gating scheme with typical GFP+ and GFP frequencies for FACS of a Ptc; Sox2-eGFP tumor depleted for cells expressing CD45 or Ter-119.
(B) Typical FACS plot showing CD15+ and Sox2+ cell frequencies in primary Ptc; Sox2-eGFP tumor cells.
(C) Breakdown of Sox2+ cells by their expression of CD15 (top) and CD15+ cells by their expression of Sox2 (bottom) (n = 3 per group, mean ± SEM). n.d., no data.
(D) In vitro limiting dilution analysis comparing colony-forming cell (CFC) frequency in primary Sox2+ and Sox2 Ptc tumor cells. (estimate plus upper limit,
c2 = 34.0, p < 0.0001).
(E) In vivo limiting dilution analysis comparingmedulloblastoma-propagating cell (MPC) frequency of primary Sox2+ and Sox2 Ptc tumor cells. A summary of the
frequency of allograft formation at each cell dose injected is shown at the right (estimate plus upper limit, c2 = 11.1, p < 0.001).
(F) Representative hematoxylin and eosin stain of an allograft tumor derived from Sox2-eGFP+ cells. Scale bar, 100 mm.
(G) Representative Sox2 and GFP colocalization in an allograft tumor derived from Sox2-eGFP+ cells. DAPI is shown in white. Scale bar, 20 mm.
(H and I) Representative DCX (H) and NeuN (I) expression in an allograft tumor derived from Sox2-eGFP+ cells. DAPI is shown in white. Scale bar, 20 mm.
See also Figure S3.
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Quiescent Sox2+ Cells Drive Medulloblastomatumor cell self-renewal is to perform orthotopic allografts at
limiting dilutions in immunodeficient mice. In our in vivo limiting
dilution analysis (LDA), primary Sox2+ cells exhibited a signifi-
cantly higher tumor-propagating potential than the Sox2 cells
comprising the tumor bulk (p < 0.001) (Figure 3E). Sox2 cells ex-
hibited a limited self-renewal capacity, reliably forming tumors
only at the highest cell dose injected (Figure 3E). Importantly,
subclonal dilutions of uniform Sox2+ cells recapitulated the het-
erogeneity of the primary tumors from which they were derived,containing rare Sox2+ cells and abundant DCX+ and NeuN+ cells
(Figures 3F–3I). Therefore, Sox2+ cells both self-renew and
differentiate in vivo and are MB-propagating cells (MPCs).
Lineage Tracing Confirms That Sox2+ Cells Are
Tumor-Propagating
Genetic lineage tracing has recently been used to demonstrate
the hierarchical nature of squamous skin tumors and intestinal
adenomas (Driessens et al., 2012; Schepers et al., 2012). OneCancer Cell 26, 33–47, July 14, 2014 ª2014 Elsevier Inc. 37
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Figure 4. Sox2+ Cells Propagate Ptc MBs In
Situ
(A) To perform lineage tracing in MB, mice with a
loxP-stop-loxP tdTomato reporter gene at the
Rosa 26 locus and Sox2creER knockin mice were
crossed to the Ptc model.
(B) Quantification of the frequency of cells labeled
with tdTomato within the Sox2+ tumor population
following a 5 mg tamoxifen injection (n = 3–5 per
time point, mean ± SEM).
(C) Quantification of tdTomato labeling of tumor
cells following a 5 mg tamoxifen injection
(n = 4–6 per time point, mean ± SEM).
(D) Representative images of tumor labeling with
tdTomato at 24 hr, 7 days, and 42 days post-
tamoxifen. DAPI is shown in white. Scale bar,
11 mm.
See also Figure S4.
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Quiescent Sox2+ Cells Drive Medulloblastomaoutstanding question is whether cells from tumors manipulated
ex vivo that transplant malignancies in immunodeficient mice
also sustain primary tumor growth. To determine whether
Sox2+ cells self-renew and differentiate in situ in primary
tumors, we crossed Sox2-creERT2 (Arnold et al., 2011) and
Rosa26 CAG-loxP-stop-loxP-tdTomato mice to Ptc mice to
genetically mark Sox2+ tumor cells upon administration of
tamoxifen (Figure 4A). To define the lineage of Sox2+ cells,
6-week-old mice were administered a single 5 mg dose of
tamoxifen and sacrificed on successive days thereafter.
Recombination was initially highly specific to Sox2-expressing
cells (Figure S4). The frequency of marked Sox2+ cells re-
mained constant throughout the tracing period, confirming
that this population is self-renewing (Figure 4B). Over time,
the frequency of tdTomato+ tumor cells increased progressively
until, after 6 weeks, nearly one-third of tumor cells were posi-
tive and, thus, derived from the Sox2+ cells marked at the
time of injection (Figures 4C and 4D). At 21 days post-tamox-
ifen, tdTomato expression was maintained in the Sox2+ fraction
and also observed in cells expressing the neuronal markers
DCX, bIII-tubulin, and NeuN as well as in cells expressing the
glial markers GFAP or S100-b (Figures 5A–5D; Figure S5).
Therefore, rare Sox2+ cells both self-renew and differentiate
into the fast-dividing progenitor-like cells and postmitotic
neuron-like cells that comprise the majority of the tumor. The
frequency of tdTomato+ cells expressing NeuN increased with
similar kinetics to tumor labeling, suggesting that tumor growth
mimics neurogenesis (Figure 5E). Collectively, these data sup-
port a model for MB growth in primary tumors and allografts
driven by self-renewing Sox2+ cells.38 Cancer Cell 26, 33–47, July 14, 2014 ª2014 Elsevier Inc.MPCs Are Enriched following
Antimitotic and Shh-Targeted
Therapy
Conventional therapies ablate the ma-
jority of acute myeloid leukemia (AML)
cells and control the disease burden but
spare quiescent leukemia-initiating cells,
the believed source of relapse (Saito
et al., 2010). To test the effects of antimi-
totic therapy on primaryMBs, 70-day-oldtumor-bearing mice were infused intracranially with saline
vehicle or 2% Ara-C (cytarabine) for 5 days and injected with
EdU 3 hr prior to sacrifice (Figure 6A). Ara-C is an S phase-
specific chemotherapy agent that has been administered intra-
thecally to MB patients and to mice in prior studies of quiescent
neural stem cells (Doetsch et al., 1999; Partap et al., 2011). EdU
incorporation 3 hr post-treatment was reduced significantly in
Ara-C-treatedmice, indicating the successful targeting ofmitotic
cells (Figure 6B; Figure S6A). Interestingly, the frequency of
Sox2+ tumor cells increased significantly after mitotic inhibition
(Figure 6C; Figure S6B). Together, these results show that
MPCs are resistant to antimitotic therapy and suggest that
they may act as a reservoir for disease relapse.
GDC-0449 (vismodegib), an inhibitor of the SHH signaling
transducer Smoothened, is used to treat basal cell carcinoma
patients and is in clinical trials to abrogate dysregulated, onco-
genic SHH signaling in MB and other SHH-driven cancers
(Robarge et al., 2009). To examine the sensitivity of MPCs to
GDC-0449, day 70 Ptc mice were treated once daily with
GDC-0449 or vehicle for 5 days and injected with EdU 3 hr prior
to sacrifice (Figure 6D; Figures S6C and S6D). EdU incorporation
was abolished in GDC-0449-treated tumors (Figure 6E and Fig-
ure S6E), indicating a dependence of proliferating tumor cells on
Shh signaling. GDC-0449 treatment also increased apoptosis
and decreased the frequency of DCX+ cells (Figures S6G and
S6H). Accordingly, Sox2+ cells were significantly enriched in
the residual tumors (Figure 6F; Figure S6F).
To exclude the possibility that therapy induces the expression
of Sox2 and to test the contribution of MPCs to tumor regrowth,
we performed lineage traces in vehicle- and GDC-0449-treated
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(A–D) Representative image of tdTomato labeled Sox2+ (A), DCX+ (B), NeuN+ (C), and bIII-tubulin+ (D) cells at 21 days of tracing. Scale bars, 11 mm.
(E) The fraction of tdTomato+ tumor cells that are NeuN+ increases over time (n = 3 per time point, mean ± SEM). Scale bars, 11 mm.
See also Figure S5.
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Figure 6. MPCs Are Enriched following Antimitotic Chemotherapy and Smoothened Inhibition
(A) Day 70 Ptc mice were administered 2%Ara-C or saline vehicle intracranially bymicro-osmotic pump for 5 days and then injected with 30mg/kg EdU 3 hr prior
to sacrifice (sac) on treatment day 5.
(B) Quantification of EdU incorporation in saline- and Ara-C-treated Ptc tumors (n = 4 per group, mean ± SEM, two-tailed unpaired t test).
(C) Quantification of Sox2+ cell frequency in saline and Ara-C treated Ptc tumors (n = 6 per group, mean ± SEM, two-tailed unpaired t test).
(D) Day 70 Ptc mice were administered methylcellulose Tween 80 (MCT) vehicle or 50mg/kg GDC-0449 once daily for 5 days (arrows) and injected with 30mg/kg
EdU 3 hr prior to sacrifice.
(E) Quantification of EdU incorporation in MCT- and GDC-0449-treated tumors (n = 5 per group, mean ± SEM, two-tailed unpaired t test).
(F) Quantification of Sox2+ cell frequency in MCT- and GDC-0449-treated tumors (n = 5 per group, mean ± SEM, two-tailed unpaired t test).
(G) Day 70 Ptc; Sox2creER; loxP-stop-loxP tdTomatomicewere administered tamoxifen 48 hr prior to a 5-day treatment with 50mg/kgGDC-0449 orMCT vehicle
once daily (arrows) and were chased for 7 days post-therapy.
(H) Representative images of tdTomato labeling in MCT vehicle- or GDC-0449-treated tumors 7 days post-treatment. DAPI is shown in white. Scale bars,
40 mm.
(I) Quantification of (H) (n = 4 mice per group, mean ± SEM, two-tailed unpaired t test).
See also Figure S6.
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Quiescent Sox2+ Cells Drive MedulloblastomaPtc mice (Figure 6G). Tumor-bearing mice were injected with
tamoxifen to genetically mark Sox2+ cells 48 hr prior to a
5-day course of GDC-0449 or vehicle treatment and sacrificed
7 days after the final dose. Tumors from GDC-0449-treated
mice contained significantly higher frequencies (40 ± 3.5 versus
21 ± 4%, p = 0.01) of tdTomato+ cells, indicating that cells ex-
pressing Sox2 prior to treatment are selected by Smoothened
inhibition (Figures 6H and 6I). Collectively, this indicates that
MPCs are spared by therapies that target cycling cells in the
tumor bulk and are likely responsible for tumor relapse following
therapy.
MPCs Express a Quiescent Stem Cell Gene Signature
To investigate the biology of MPCs, we sorted Sox2+ and Sox2
cells from primary Sox2-eGFP mouse tumors (Figure 3A) and
compared the gene expression profiles of the two populations.
Sox2+ and Sox2 derived samples clustered separately in a 3D
principal component analysis, indicating nonoverlapping molec-
ular profiles (Figure 7A). MPCs are, therefore, functionally and
transcriptionally distinct from the tumor bulk. Sox2+ cells ex-
hibited a distinct gene expression profile defined by differential
expression of 628 genes (false discovery rate (FDR), 0.05),
including many expressed by neural stem cells such as Sox2,
Gfap,Olig1,Olig2,Blbp, and Pdgfra (Figure 7B; Table S1). Genes
encoding several CD15 carrier proteins, including Lrp1 and
Ptprz1, were highly expressed in Sox2+ cells. Sox2 cells ex-
pressed a more differentiated gene expression profile, being
significantly enriched for neuronal lineage genes, including
Pax6, Atoh1, Dcx, Rbfox3 (NeuN), and Zic2 (Figure 7B; Table
S1). Differential expression levels of several genes were
confirmed by quantitative PCR analysis (Figure S7A).
Interrogating Sox2+ and Sox2 expression profiles using both
ingenuity pathway analysis and gene set enrichment analysis
(GSEA) suggested no differences in Shh pathway activation be-
tween the two populations (data not shown). These results were
confirmed by quantitative PCR analysis of Shh pathway target
genes Gli1 and Hhip, which were expressed at similar levels in
Sox2+ and Sox2 cells (Figure S7B). Therefore, Sox2+ cells
exhibit active Shh signaling but are resistant to the Smoothened
inhibitor GDC-0449.
Next, we used GSEA to investigate transcriptional similarities
between MPCs expressing Sox2 and previously characterized
quiescent cell populations. Sets of genes significantly upregu-
lated in multiple quiescent stem cell populations, including
neural stem cells (Martynoga et al., 2013), were highly enriched
in Sox2-expressing cells (Figure 7C; Figure S7C). A gene set
derived from rapidly cycling granule neuron progenitor cells
(Li et al., 2013) was enriched significantly in the Sox2 popula-
tion, confirming these cells’ proliferative and differentiated
character (Figure 7C). Therefore, MPCs exhibit a quiescent
stem cell gene signature and may utilize common molecular
mechanisms to maintain their quiescence and self-renewal
ability.
An MPC Signature Defines SHH MB Patients with a Poor
Prognosis
For multiple malignancies, patients whose cancer exhibits a
greater expression of stem cell genes have a significantly worse
prognosis (Eppert et al., 2011; Liu et al., 2007; Merlos-Sua´rezet al., 2011; Zheng et al., 2013). To determine whether this was
also true for MB, we derived a MPC gene signature from the
human homologs of genes expressed significantly differentially
in mouse MPCs (Figure 7B) and analyzed gene expression
profiles from 83 SHH subgroup human MBs for their relative
expression of these genes. Consensus clustering and unsuper-
vised hierarchical clustering revealed three distinct groups with
high, intermediate, and low levels of MPC signature expression
(Figures 7D and 7E; Figures S7D and S7E). The three groups
were highly reproducible between the two methods, with only
one discordant case. Patients with tumors of the MPC high
group comprised 12% percent of all SHH subgroup MBs and
had a significantly worse prognosis (p = 0.03) than those in the
MPC intermediate and low groups (Figure 7F; Figure S7F).
Patients with a high expression of theMPC signature were signif-
icantly enriched for tumors with large cell anaplastic histology
(Figure S7G).
To substantiate the correlation between the MPC signature
and patient outcome, we assessed a clinically well annotated
MB tissue microarray containing more than 300 primary tumor
samples. The SOX2 protein level was classified in a semiquanti-
tative fashion, segregating tumors in to two groups: high SOX2
and low SOX2 (Figure 7G). High SOX2-expressing tumors with
20% or greater immunoreactivity were significantly more com-
mon within SHH subgroup and Group 3 MBs (Figure S7H). We
found that high SOX2 expression was associated with signifi-
cantly worse overall survival in SHH subgroup patients from
this independent cohort (Figure 7H). Remarkably, no patients
with low SOX2 immunoreactivity died during follow-up. Taken
together, these findings indicate a clinical relevance for SOX2+
MB cells.
Targeting Sox2+ Cells in SHH MB
Our data suggest that targeting SOX2+ cells in SHH MB could
improve patient outcome. To identify pharmaceuticals that
affect SOX2+ cells, we turned to primary patient-derived cul-
tures from human SHH MB tumors that uniformly express
SOX2 when grown under serum-free conditions (Figure 8A).
Human SHH MB cultures did not respond to GDC-0449 at ther-
apeutically relevant doses (Figure 8B). Self-renewal of primary
Ptc and two freshly resected human SHH MBs (M693 and
M698) was not affected by 5 mMGDC-0449 in in vitro LDAs (Fig-
ure 8C–8E). Whole genome sequencing of M693 and RNA
sequencing of M698 identified stereotyped activating mutations
in the SHH pathway that are predicted to respond to GDC-0449
(Figures S8A and S8B), suggesting that cell type-specific drug
responses may also occur in human tumors. We then screened
our four human patient-derived SHH MB cultures with the 97-
compound National Cancer Institute (NCI) oncology drug set in
search of agents to which SOX2+ MB cells are sensitive. The
top 15 hits (Figure 8F) included two aureolic acids, dactinomycin
and mithramycin (MM). Because MM is known to cross the
blood-brain barrier, it was prioritized for follow-up. Human
SHH medulloblastoma primary cultures were sensitive to nano-
molar concentrations of MM (Figure 8G). Similarly, 25 nM MM
significantly inhibited sphere formation by primary Ptc cells, indi-
cating a similar effectiveness against mouse cells (Figure 8H).
Secondary sphere formation was abrogated in MM-treated Ptc
cells even in the absence of drug (Figure 8I). Strikingly, MMCancer Cell 26, 33–47, July 14, 2014 ª2014 Elsevier Inc. 41
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Figure 7. Sox2+ MB Cells Have a Quiescent Stem Cell Gene Signature that Predicts a Poor Prognosis in Human SHH MB
(A) Principle component analysis of gene expression profiles of primary Sox2+ and Sox2 Ptc cells (n = 4 per group).
(B) Hierarchical clustering of four matched primary Sox2+ and Sox2 samples based on the 628 genes expressed differentially between the two groups (one-way
ANOVA, FDR < 0.05, fold change is shown).
(C) GSEA comparing Sox2+ and Sox2 cells for enrichment of a quiescent neural stem cell gene set (top) and a granule neuron progenitor gene set (bottom). NES,
normalized enrichment score.
(D) Consensus clustering by k-means of 82 SHH subgroup MBs based on a mouse MPC gene signature yields three distinct groups.
(E) Hierarchical clustering of 82 SHH subgroup MBs based on a mouse MPC gene signature yields three identical groups to consensus clustering except for one
outlier.
(F) Kaplan-Meier curve showing overall survival of patients with high, intermediate, or low expression of a MPC gene signature (n = 76, log rank test).
(G) Representative images from a tissue microarray of humanMB samples exhibiting low and high frequency of SOX2+ cells. SOX2 reactivity was detected using
3,30-diaminobenzidine (brown), and tissues were counterstained with hematoxylin and eosin. Scale bar, 50 mm.
(H) Kaplan-Meier curve showing overall survival of SHH MB patients with high or low frequencies of Sox2+ cells (n = 98, log rank test).
See also Figure S7 and Table S1.
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allografts (Figure 8J). Drugs like MM, whose targets include
SOX2+ cells, may present an effective therapeutic avenue for
SHH MB.42 Cancer Cell 26, 33–47, July 14, 2014 ª2014 Elsevier Inc.DISCUSSION
Here we dissect the role of SHH MB’s constituent cell types in
tumor maintenance and relapse to establish a paradigm for
Cancer Cell
Quiescent Sox2+ Cells Drive Medulloblastomadisease progression as a hierarchy that mirrors a neurogenic
program. We characterized a functionally defined MB-propa-
gating cell population as cycling slowly. This has important
clinical implications because most MB therapies, including
chemotherapeutic agents and ionizing radiation, preferentially
affect cycling cells. Perivascular nestin+ cells were radiation-
resistant in another Shh-driven MB model (Hambardzumyan
et al., 2008), and a more recent study found that quiescent
nestin+ glioma cells contribute to tumor regrowth following
chemotherapy (Chen et al., 2012). Therefore, as in hematological
malignancies, quiescence may be a common trait of multiple
types of brain tumor stem cells. Understanding the mechanisms
that govern the quiescent Sox2+ statemay present opportunities
for tailored therapy that could extend beyond MB. Breaking the
quiescence of chronic myelogenous leukemia stem cells by in-
hibiting prosurvival B cell lymphoma 2 (BCL2) family members
or blocking promyelocytic leukemia sensitizes them to tyrosine
kinase inhibition or Ara-C ablation, respectively (Goff et al.,
2013; Ito et al., 2008). Disrupting regulators of the quiescent
state is an appealing therapeutic option for MB that may sensi-
tize MPCs to conventional therapies.
Our label-chase studies and apoptotic analysis revealed that
the majority of differentiated Ptc tumor cells constantly turn
over but exhibit limited self-renewal in functional assays. Inter-
estingly, SHH MB models in which proapoptotic genes are
deleted exhibit the paradox of increased differentiation and
reduced tumor latency (Garcia et al., 2013). We propose that,
in such models, NeuN+ cells accumulate because of impaired
apoptosis, inflating tumor volume causing mass effects, disease
manifestation, and death. In retrospective studies, patients
whose MBs showed higher levels of neuronal differentiation
experienced greater overall survival (Grotzer et al., 2000; Miya-
hara et al., 2014).
Adult and developmental neurogenesis, including generation
of the granule neurons in the cerebellum, begins with multipotent
neural stem cell differentiation into a progenitor pool that ex-
pands transiently and, ultimately, produces mature neurons
(Hatten and Roussel, 2011; Ming and Song, 2011). Targeting
constitutively active Smo mutations or Ptch1 deletions to cells
expressing GFAP and stem cell markers in the embryonic day
14 (E14) rhombic lip (Schu¨ller et al., 2008), Sox2+ cells in the
E14.5 external germinal layer (EGL) (Ahlfeld et al., 2013), or
unipotent nestin+ progenitors in the postnatal EGL (Li et al.,
2013) induces formation of Shh-subgroup MBs. Our work sug-
gests that continued tumor growth and relapse are driven by
cells expressing these same markers.
The modern definition of a cancer stem cell is one that can be
isolated prospectively from a primary malignancy to engraft an
immunodeficient mouse and phenocopy the original disease
(Nguyen et al., 2012; Reya et al., 2001). Immunophenotype alone
has been shown subsequently to be inadequate for cancer stem
cell identification (Goardon et al., 2011), and cancers for which
tumor-propagating cells are not rare have been cited as evi-
dence in favor of a stochastic versus hierarchical model for
tumor growth (Goardon et al., 2011; Quintana et al., 2010; Son
et al., 2009). More recently, studies using animal models of
intestinal adenocarcinoma and squamous skin tumors demon-
strated clonal-level hierarchical tumor growth from stem cells
that self-renew and differentiate, presenting strong evidence infavor of the cancer stem cell hypothesis (Driessens et al.,
2012; Schepers et al., 2012). Our work reconciles transplantation
and lineage tracing approaches by using both prospective isola-
tion and genetic fate mapping to show that Sox2+ cells propa-
gate MB. That both methods support a Sox2+ cell-driven model
suggests that functionally defined tumor-propagating cells from
human tumors may also drive growth in patients’ cancers, which
would make them essential therapeutic targets.
As predicted by prior transplantation studies, our results
support a hierarchical model for MB growth. MPCs expressing
Sox2 were long-lived, self-renewing, and drove growth in
primary and allograft tumors. Sorted Sox2 cells exhibited a
10-fold lower tumor-propagating cell frequency, indicating
diminished self-renewal. Despite being highly proliferative,
DCX+ cells differentiated into postmitotic NeuN-expressing cells
that are short-lived, minimizing their impact on long-term growth.
Fate mapping from differentiated cell types will be necessary to
confirm the hierarchical nature of tumors, including MB, and
address the possible reacquisition of stem cell properties by sto-
chastic fate switching between differentiated and stem cell
states in vivo (Meacham and Morrison, 2013).
The prognostic significance of SOX2 expression programs
and SOX2+ cell frequency in human tumors confirms the clinical
relevance of MPCs. Tumor progression likely selects for cells
with a long-term propagating potential, thus enriching these
cells in advanced disease (Kreso and Dick, 2014). Stem cell sig-
natures shared by hematopoietic and leukemia stem cells pre-
dicted AML patient survival despite leukemia stem cells’ quies-
cence and low frequency within AML samples (Eppert et al.,
2011). Similarly, in breast, colon, and non-small cell lung cancer,
stem cell signature expression correlates inversely with outcome
(Liu et al., 2007;Merlos-Sua´rez et al., 2011; Zheng et al., 2013). In
pediatric and adult brain tumors, samples with high frequencies
of functionally defined stem cells come from patients experi-
encing worse outcomes (Laks et al., 2009; Panosyan et al.,
2010). In these cancers and MB, we propose that the degree
of the stem or propagating cell signature at the gene or protein
level relates to the size of the clinically essential pool that can
cause relapse. The high frequency of Sox2+ cells in many SHH
MB patient samples indicates that not every positive cell is
necessarily a tumor-propagating or stem cell. As in glioblastoma,
the combinatorial expression of critical stem cell regulators likely
defines the MPC state (Suva` et al., 2014). Greater numbers of
SOX2+ cells may reflect an increase in MPC frequency and the
persistence of treatment resistant biology in tumor bulk that
together correlate with the likelihood that a patient will relapse.
Tumor-propagating cells in multiple model systems exhibit
resistance to traditional therapies that effectively target the
tumor bulk (Chen et al., 2012; O’Brien et al., 2012; Zheng
et al., 2013). We show that, despite exhibiting Shh-pathway
activity, MPCs are enriched following antimitotic and Smooth-
ened inhibition and that SOX2+ cells from human SHH MB do
not respond to GDC-0449 in vitro. Drug sensitivity is, therefore,
a functional property that varies between the heterogeneous
cell types comprising MB. Greater lineage traces from Sox2+
cells following therapy suggests that MPCs are the units of
selection responsible for MB relapse. Current treatment may
successfully control disease bulk but spare critical cells that
regrow the tumor. Mithramycin, a drug that is highly effectiveCancer Cell 26, 33–47, July 14, 2014 ª2014 Elsevier Inc. 43
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Figure 8. SOX2+ Cells Can Be Targeted Using Mithramycin
(A) A representative immunofluorescence image of cells derived from a human SHHMB tumor expressing SOX2 and the neural stem cell marker nestin. Scale bar,
20 mm.
(B) Human SHH MB cell viability was measured by Alamar Blue fluorescence at 591 nm after 5 days of treatment with increasing concentrations of GDC-0449
(mean ± SEM normalized to DMSO control).
(C) In vitro LDA comparing sphere-forming cell (SFC) frequency of primary Ptc cells treated with DMSO or 5 mM GDC-0449 (c2 = 03.42, p = 0.064).
(D and E) Primary human SHH MB cells from patient M693 (c2 = 2.6, p = 0.107 [D]) or patient M698 (c2 = 0.141, p = 0.707 [E]) were plated in an in vitro LDA
comparing SFC frequency in neural stem cell medium containing DMSO or 5 mM GDC-0449.
(F) The top 15 hits from a screen of four human SHH MB cultures with the NCI oncology drug set. Cell viability was assessed by Alamar Blue fluorescence at
591 nm (n = 4, mean ± SEM, normalized to DMSO).
(legend continued on next page)
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Quiescent Sox2+ Cells Drive Medulloblastomaagainst Sox2+ mouse and human SHH MB cells in vitro, stops
allograft tumor growth. Therefore, MM may be effective in
preventing disease relapse. Because DCX+ cells are cycling
rapidly and Sox2 cells form tumors reliably at high cell doses,
this fraction possesses some tumor-propagating capacity.
Solely targeting a rare, relatively quiescent tumor propagating
population may, therefore, be insufficient to control disease.
Indeed, in glioma-bearing mice, the tumor burden was most
reduced when quiescent nestin+ cells were ablated genetically
in parallel to temozolomide treatment of cycling cells (Chen
et al., 2012). Eradicating quiescent MPCs in parallel to tumor
debulking using GDC-0449 or other agents may be required
for optimal therapeutic specificity yielding the most durable
MB remission.EXPERIMENTAL PROCEDURES
Mice
Ptch1+/ mice (Goodrich et al., 1997) were maintained by breeding with CD1
mice from The Jackson Laboratory. Sox2creER mice (Arnold et al., 2011)
and Sox2-eGFP mice (Ellis et al., 2004) (provided by Dr. Freda Miller, Toronto
Hospital for Sick Children) were crossed to CD1 Patched1+/ mice.
B6;129S6-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J (Rosa-CAG-LSL-tdTomato)
and 5- to 7-week-old NOD.Gc-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were
purchased from The Jackson Laboratory. Experimental Ptc mice were admin-
istered 3 Gy g-radiation from a cesium 137 source at birth. 50 mg/kg GDC-
0449 (Selleck Chemical) was administered once daily in 0.5% methylcellulose
0.2% Tween 80 buffer by gastric gavage. Cytarabine (Ara-C, Sigma) or 0.9%
saline vehicle was delivered by intracranial micro-osmotic pump for 5 days
as described previously (Doetsch et al., 1997). Cre recombination for lineage
tracing was achieved by injecting 6-week-old mice intraperitoneally with
5 mg tamoxifen (Sigma) dissolved in sesame oil. Subcutaneous tumor-bearing
NSG mice were administered mithramycin (Cayman Chemical) by intraperito-
neal injection in PBS vehicle onMondays, Wednesdays, and Fridays for a total
of nine doses. Mice were housed at The Hospital for Sick Children Laboratory
Animal Services. All experimental procedures were approved by The Hospital
for Sick Children’s Animal Care Committee. Further experimental details are
provided in the Supplemental Experimental Procedures.
Patient Samples
All tumor samples were procured after receiving informed consent from
patients, and all experimental procedures were performed in accordance
with the Research Ethics Board at The Hospital for Sick Children (Toronto,
Canada) and the respective collaborating institutions. Approval to link labora-
tory data to clinical and pathological data was obtained from the respective
institutional review boards.
Fluorescence-Activated Cell Sorting
Primary tumors from Ptc; Sox2-eGFP mice were dissociated in PBS, and cell
sorting was performed on either a Beckman Coulter MoFlo or Beckman
Coulter MoFlo-XDP. Data were analyzed using FloJo software. Gates were
established using CD1 Ptc tumor cells and fluorescence 1 controls.
Microglia, hematopoietic cells, and red blood cells were depleted from sorted
samples by gating out CD45+ cells (microglia and hematopoietic cells) and
Ter-119+ cells (red blood cells).(G) Human SHH-MB cell viability was measured by Alamar Blue fluorescence at 5
SEM, normalized to DMSO).
(H) In vitro LDA comparing SFC frequency between primary Ptc cells treated with
(I) Secondary LDA of primary spheres from (H) plated without drug (n = 3 tumors
(J) NSG mice engrafted subcutaneously with 5 3 105 Ptc cells were randomized
when tumorswere first palpable andwere treated until mice treatedwith PBS reac
unpaired t test.
Bar charts for LDAs in (C–E), (H), and (I) are shown as estimate plus upper limit.Gene Expression Analysis
Microarray analysis was performed using the Affymetrix Mouse Gene 2.0 ST
array on four biological replicates of matched pooled primary Sox2+ and
Sox2 cells from primary Ptc; Sox2-eGFP FACS-sorted tumors (three
pooled sorts of Sox2+ or Sox2 cells to one biological replicate). Microarray
data were first processed using robust multichip analysis normalization.
Principal component analysis and hierarchical clustering were performed
using Partek Genomics Suite 6.6. Differentially expressed genes were
detected by one-way ANOVA in Partek Genomics Suite 6.6 with an FDR
of < 0.05 and analyzed by ingenuity pathway analysis (Ingenuity Systems).
GSEA was performed using GSEA v2.0.12 with probes ranked by t test,
and significance was determined by 2000 phenotype permutations (Subra-
manian et al., 2005). The minimum gene set size was 8, and the maximum
was 650. Multiple probe sets per gene were collapsed using the median
of probes.Statistical Methods
Data were analyzed and statistics performed using GraphPad Prism v6.0b.
Limiting dilution analyses were analyzed using extreme limiting dilution anal-
ysis (Hu and Smyth, 2009). Pooled data are reported as the mean ± SEM.ACCESSION NUMBERS
The GenBank accession numbers for the microarray data described in this
publication are GSE48766 (mouse) and GSE50765 (human). The European
Bioinformatics Institute accession number for DNA and RNA sequencing
data described in this publication is EGAD00001000818.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
eight figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2014.05.005.ACKNOWLEDGMENTS
P.D. and M.T. hold Garron Family Research Chairs in Childhood Cancer
Research and are supported by grants from the Canadian Institutes of Health
Research (CIHR), the Ontario Institute for Cancer Research with funds from the
Government of Ontario, and Genome Canada. P.D. also receives funding from
the Canadian Cancer Society, the Hospital for Sick Children Foundation, Jes-
sica’s Footprint Foundation, the Hopeful Minds Foundation, and B.R.A.I.N.
Child. M.T.’s lab is also supported by Genome BC, the Terry Fox Research
Institute, the Pediatric Oncology Group Ontario, funds from the family of
Kathleen Lorette and the Clark H. Smith Brain Tumour Centre, the Montreal
Children’s Hospital Foundation and the Hospital for Sick Children Sonia and
Arthur Labatt Brain Tumour Research Centre, the Chief of Research Fund,
the Cancer Genetics Program, and B.R.A.I.N. Child. K.H. is supported by an
NIH grant (5R01DK096034-02). R.V. is funded by a CIHR Vanier Canada grad-
uate scholarship. We would like to thank the Sickkids-UHN Flow Cytometry
Facility and Sickkids Imaging Facility for contributions to this work.
Received: September 27, 2013
Revised: January 28, 2014
Accepted: May 12, 2014
Published: June 19, 201491 nm after 5 days of treatment with increasing doses of mithramycin (mean ±
the DMSO control or 25 nM mithramycin (n = 4 tumors, c2 = 219, p < 0.0001).
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See also Figure S8.
Cancer Cell 26, 33–47, July 14, 2014 ª2014 Elsevier Inc. 45
Cancer Cell
Quiescent Sox2+ Cells Drive MedulloblastomaREFERENCES
Ahlfeld, J., Favaro, R., Pagella, P., Kretzschmar, H.A., Nicolis, S., and Schu¨ller,
U. (2013). Sox2 requirement in sonic hedgehog-associated medulloblastoma.
Cancer Res. 73, 3796–3807.
Arnold, K., Sarkar, A., Yram, M.A., Polo, J.M., Bronson, R., Sengupta, S.,
Seandel, M., Geijsen, N., and Hochedlinger, K. (2011). Sox2(+) adult stem
and progenitor cells are important for tissue regeneration and survival of
mice. Cell Stem Cell 9, 317–329.
Bailey, P., and Cushing, H. (1925). Medulloblastoma cerebelli: A common type
of midcerebellar glioma of childhood. Arch. Neurol. Psychiatry 14, 192–224.
Chen, J., Li, Y., Yu, T.S., McKay, R.M., Burns, D.K., Kernie, S.G., and Parada,
L.F. (2012). A restricted cell population propagates glioblastoma growth after
chemotherapy. Nature 488, 522–526.
Crawford, J.R., MacDonald, T.J., and Packer, R.J. (2007). Medulloblastoma in
childhood: new biological advances. Lancet Neurol. 6, 1073–1085.
Doetsch, F., Garcı´a-Verdugo, J.M., and Alvarez-Buylla, A. (1997). Cellular
composition and three-dimensional organization of the subventricular
germinal zone in the adult mammalian brain. J. Neurosci. 17, 5046–5061.
Doetsch, F., Caille´, I., Lim, D.A., Garcı´a-Verdugo, J.M., and Alvarez-Buylla, A.
(1999). Subventricular zone astrocytes are neural stem cells in the adult
mammalian brain. Cell 97, 703–716.
Driessens, G., Beck, B., Caauwe, A., Simons, B.D., and Blanpain, C. (2012).
Defining the mode of tumour growth by clonal analysis. Nature 488, 527–530.
Ellis, P., Fagan, B.M., Magness, S.T., Hutton, S., Taranova, O., Hayashi, S.,
McMahon, A., Rao, M., and Pevny, L. (2004). SOX2, a persistent marker for
multipotential neural stem cells derived from embryonic stem cells, the embryo
or the adult. Dev. Neurosci. 26, 148–165.
Eppert, K., Takenaka, K., Lechman, E.R., Waldron, L., Nilsson, B., van Galen,
P., Metzeler, K.H., Poeppl, A., Ling, V., Beyene, J., et al. (2011). Stem cell gene
expression programs influence clinical outcome in human leukemia. Nat. Med.
17, 1086–1093.
Garcia, I., Crowther, A.J., Gama, V., Ryan Miller, C., Deshmukh, M., and
Gershon, T.R. (2013). Bax deficiency prolongs cerebellar neurogenesis, accel-
erates medulloblastoma formation and paradoxically increases both malig-
nancy and differentiation. Oncogene 32, 2304–2314.
Goardon, N., Marchi, E., Atzberger, A., Quek, L., Schuh, A., Soneji, S., Woll, P.,
Mead, A., Alford, K.A., Rout, R., et al. (2011). Coexistence of LMPP-like and
GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 19,
138–152.
Goff, D.J., Court Recart, A., Sadarangani, A., Chun, H.J., Barrett, C.L.,
Krajewska, M., Leu, H., Low-Marchelli, J., Ma, W., Shih, A.Y., et al. (2013). A
Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells
sensitive to tyrosine kinase inhibition. Cell Stem Cell 12, 316–328.
Goodrich, L.V., Milenkovic, L., Higgins, K.M., and Scott, M.P. (1997). Altered
neural cell fates and medulloblastoma in mouse patched mutants. Science
277, 1109–1113.
Grotzer, M.A., Janss, A.J., Fung, K., Biegel, J.A., Sutton, L.N., Rorke, L.B.,
Zhao, H., Cnaan, A., Phillips, P.C., Lee, V.M., and Trojanowski, J.Q. (2000).
TrkC expression predicts good clinical outcome in primitive neuroectodermal
brain tumors. J. Clin. Oncol. 18, 1027–1035.
Guan, Y., Gerhard, B., and Hogge, D.E. (2003). Detection, isolation, and stim-
ulation of quiescent primitive leukemic progenitor cells from patients with
acute myeloid leukemia (AML). Blood 101, 3142–3149.
Hambardzumyan, D., Becher, O.J., Rosenblum, M.K., Pandolfi, P.P., Manova-
Todorova, K., and Holland, E.C. (2008). PI3K pathway regulates survival of
cancer stem cells residing in the perivascular niche following radiation in
medulloblastoma in vivo. Genes Dev. 22, 436–448.
Hatten, M.E., and Roussel, M.F. (2011). Development and cancer of the cere-
bellum. Trends Neurosci. 34, 134–142.
Holyoake, T., Jiang, X., Eaves, C., and Eaves, A. (1999). Isolation of a highly
quiescent subpopulation of primitive leukemic cells in chronic myeloid leuke-
mia. Blood 94, 2056–2064.46 Cancer Cell 26, 33–47, July 14, 2014 ª2014 Elsevier Inc.Hu, Y., and Smyth, G.K. (2009). ELDA: extreme limiting dilution analysis for
comparing depleted and enriched populations in stem cell and other assays.
J. Immunol. Methods 347, 70–78.
Ito, K., Bernardi, R., Morotti, A., Matsuoka, S., Saglio, G., Ikeda, Y., Rosenblatt,
J., Avigan, D.E., Teruya-Feldstein, J., and Pandolfi, P.P. (2008). PML targeting
eradicates quiescent leukaemia-initiating cells. Nature 453, 1072–1078.
Kool, M., Jones, D.T., Ja¨ger, N., Northcott, P.A., Pugh, T.J., Hovestadt, V.,
Piro, R.M., Esparza, L.A., Markant, S.L., Remke, M., et al.; ICGC PedBrain
Tumor Project (2014). Genome sequencing of SHH medulloblastoma predicts
genotype-related response to smoothened inhibition. Cancer Cell 25,
393–405.
Kreso, A., and Dick, J.E. (2014). Evolution of the cancer stem cell model. Cell
Stem Cell 14, 275–291.
Laks, D.R., Masterman-Smith, M., Visnyei, K., Angenieux, B., Orozco, N.M.,
Foran, I., Yong, W.H., Vinters, H.V., Liau, L.M., Lazareff, J.A., et al. (2009).
Neurosphere formation is an independent predictor of clinical outcome in
malignant glioma. Stem Cells 27, 980–987.
Li, L., and Clevers, H. (2010). Coexistence of quiescent and active adult stem
cells in mammals. Science 327, 542–545.
Li, P., Du, F., Yuelling, L.W., Lin, T., Muradimova, R.E., Tricarico, R., Wang, J.,
Enikolopov, G., Bellacosa, A., Wechsler-Reya, R.J., and Yang, Z.J. (2013). A
population of Nestin-expressing progenitors in the cerebellum exhibits
increased tumorigenicity. Nat. Neurosci. 16, 1737–1744.
Liu, R., Wang, X., Chen, G.Y., Dalerba, P., Gurney, A., Hoey, T., Sherlock, G.,
Lewicki, J., Shedden, K., andClarke, M.F. (2007). The prognostic role of a gene
signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 356, 217–226.
LoRusso, P.M., Rudin, C.M., Reddy, J.C., Tibes, R., Weiss, G.J., Borad, M.J.,
Hann, C.L., Brahmer, J.R., Chang, I., Darbonne,W.C., et al. (2011). Phase I trial
of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refrac-
tory, locally advanced or metastatic solid tumors. Clin. Cancer Res. 17,
2502–2511.
Martynoga, B., Mateo, J.L., Zhou, B., Andersen, J., Achimastou, A., Urba´n, N.,
van den Berg, D., Georgopoulou, D., Hadjur, S., Wittbrodt, J., et al. (2013).
Epigenomic enhancer annotation reveals a key role for NFIX in neural stem
cell quiescence. Genes Dev. 27, 1769–1786.
Meacham, C.E., and Morrison, S.J. (2013). Tumour heterogeneity and cancer
cell plasticity. Nature 501, 328–337.
Merlos-Sua´rez, A., Barriga, F.M., Jung, P., Iglesias, M., Ce´spedes, M.V.,
Rossell, D., Sevillano, M., Hernando-Momblona, X., da Silva-Diz, V., Mun˜oz,
P., et al. (2011). The intestinal stem cell signature identifies colorectal cancer
stem cells and predicts disease relapse. Cell Stem Cell 8, 511–524.
Ming, G.L., and Song, H. (2011). Adult neurogenesis in the mammalian brain:
significant answers and significant questions. Neuron 70, 687–702.
Miyahara, H., Natsumeda, M., Yoshimura, J., Ogura, R., Okazaki, K.,
Toyoshima, Y., Fujii, Y., Takahashi, H., and Kakita, A. (2014). Neuronal differ-
entiation associated with Gli3 expression predicts favorable outcome for
patients with medulloblastoma. Neuropathology 34, 1–10.
Nguyen, L.V., Vanner, R., Dirks, P., and Eaves, C.J. (2012). Cancer stem cells:
an evolving concept. Nat. Rev. Cancer 12, 133–143.
Northcott, P.A., Jones, D.T., Kool, M., Robinson, G.W., Gilbertson, R.J., Cho,
Y.J., Pomeroy, S.L., Korshunov, A., Lichter, P., Taylor, M.D., and Pfister, S.M.
(2012). Medulloblastomics: the end of the beginning. Nat. Rev. Cancer 12,
818–834.
O’Brien, C.A., Kreso, A., Ryan, P., Hermans, K.G., Gibson, L., Wang, Y.,
Tsatsanis, A., Gallinger, S., and Dick, J.E. (2012). ID1 and ID3 regulate the
self-renewal capacity of human colon cancer-initiating cells through p21.
Cancer Cell 21, 777–792.
Panosyan, E.H., Laks, D.R., Masterman-Smith, M., Mottahedeh, J., Yong,
W.H., Cloughesy, T.F., Lazareff, J.A., Mischel, P.S., Moore, T.B., and
Kornblum, H.I. (2010). Clinical outcome in pediatric glial and embryonal brain
tumors correlates with in vitro multi-passageable neurosphere formation.
Pediatr. Blood Cancer 55, 644–651.
Cancer Cell
Quiescent Sox2+ Cells Drive MedulloblastomaPartap, S., Murphy, P.A., Vogel, H., Barnes, P.D., Edwards, M.S., and Fisher,
P.G. (2011). Liposomal cytarabine for central nervous system embryonal
tumors in children and young adults. J. Neurooncol. 103, 561–566.
Pazzaglia, S., Tanori, M., Mancuso, M., Rebessi, S., Leonardi, S., Di Majo, V.,
Covelli, V., Atkinson, M.J., Hahn, H., and Saran, A. (2006). Linking DNA
damage to medulloblastoma tumorigenesis in patched heterozygous
knockout mice. Oncogene 25, 1165–1173.
Quintana, E., Shackleton, M., Foster, H.R., Fullen, D.R., Sabel, M.S., Johnson,
T.M., and Morrison, S.J. (2010). Phenotypic heterogeneity among tumorigenic
melanoma cells from patients that is reversible and not hierarchically orga-
nized. Cancer Cell 18, 510–523.
Read, T.A., Fogarty, M.P., Markant, S.L., McLendon, R.E., Wei, Z., Ellison,
D.W., Febbo, P.G., and Wechsler-Reya, R.J. (2009). Identification of CD15
as a marker for tumor-propagating cells in a mouse model of medulloblas-
toma. Cancer Cell 15, 135–147.
Reya, T., Morrison, S.J., Clarke, M.F., and Weissman, I.L. (2001). Stem cells,
cancer, and cancer stem cells. Nature 414, 105–111.
Robarge, K.D., Brunton, S.A., Castanedo, G.M., Cui, Y., Dina, M.S.,
Goldsmith, R., Gould, S.E., Guichert, O., Gunzner, J.L., Halladay, J., et al.
(2009). GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg. Med.
Chem. Lett. 19, 5576–5581.
Roesch, A., Fukunaga-Kalabis, M., Schmidt, E.C., Zabierowski, S.E., Brafford,
P.A., Vultur, A., Basu, D., Gimotty, P., Vogt, T., and Herlyn, M. (2010). A tempo-
rarily distinct subpopulation of slow-cycling melanoma cells is required for
continuous tumor growth. Cell 141, 583–594.
Rudin, C.M., Hann, C.L., Laterra, J., Yauch, R.L., Callahan, C.A., Fu, L.,
Holcomb, T., Stinson, J., Gould, S.E., Coleman, B., et al. (2009). Treatment
of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N. Engl. J.
Med. 361, 1173–1178.
Saito, Y., Uchida, N., Tanaka, S., Suzuki, N., Tomizawa-Murasawa, M., Sone,
A., Najima, Y., Takagi, S., Aoki, Y.,Wake, A., et al. (2010). Induction of cell cycle
entry eliminates human leukemia stem cells in a mouse model of AML. Nat.
Biotechnol. 28, 275–280.
Schepers, A.G., Snippert, H.J., Stange, D.E., van den Born, M., van Es, J.H.,
van de Wetering, M., and Clevers, H. (2012). Lineage tracing reveals Lgr5+
stem cell activity in mouse intestinal adenomas. Science 337, 730–735.Schu¨ller, U., Heine, V.M., Mao, J., Kho, A.T., Dillon, A.K., Han, Y.G., Huillard,
E., Sun, T., Ligon, A.H., Qian, Y., et al. (2008). Acquisition of granule neuron
precursor identity is a critical determinant of progenitor cell competence to
form Shh-induced medulloblastoma. Cancer Cell 14, 123–134.
Singh, S.K., Hawkins, C., Clarke, I.D., Squire, J.A., Bayani, J., Hide, T.,
Henkelman, R.M., Cusimano, M.D., and Dirks, P.B. (2004). Identification of
human brain tumour initiating cells. Nature 432, 396–401.
Son, M.J., Woolard, K., Nam, D.H., Lee, J., and Fine, H.A. (2009). SSEA-1 is an
enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem
Cell 4, 440–452.
Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L.,
Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and
Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based
approach for interpreting genome-wide expression profiles. Proc. Natl.
Acad. Sci. USA 102, 15545–15550.
Suva`, M.L., Rheinbay, E., Gillespie, S.M., Patel, A.P., Wakimoto, H., Rabkin,
S.D., Riggi, N., Chi, A.S., Cahill, D.P., Nahed, B.V., et al. (2014).
Reconstructing and Reprogramming the Tumor-Propagating Potential of
Glioblastoma Stem-like Cells. Cell 157, 580–594.
Ward, R.J., Lee, L., Graham, K., Satkunendran, T., Yoshikawa, K., Ling, E.,
Harper, L., Austin, R., Nieuwenhuis, E., Clarke, I.D., et al. (2009). Multipotent
CD15+ cancer stem cells in patched-1-deficient mouse medulloblastoma.
Cancer Res. 69, 4682–4690.
Yauch, R.L., Dijkgraaf, G.J., Alicke, B., Januario, T., Ahn, C.P., Holcomb, T.,
Pujara, K., Stinson, J., Callahan, C.A., Tang, T., et al. (2009). Smoothened
mutation confers resistance to a Hedgehog pathway inhibitor in medulloblas-
toma. Science 326, 572–574.
Zeltzer, P.M., Boyett, J.M., Finlay, J.L., Albright, A.L., Rorke, L.B., Milstein,
J.M., Allen, J.C., Stevens, K.R., Stanley, P., Li, H., et al. (1999). Metastasis
stage, adjuvant treatment, and residual tumor are prognostic factors for
medulloblastoma in children: conclusions from the Children’s Cancer Group
921 randomized phase III study. J. Clin. Oncol. 17, 832–845.
Zheng, Y., de la Cruz, C.C., Sayles, L.C., Alleyne-Chin, C., Vaka, D., Knaak,
T.D., Bigos, M., Xu, Y., Hoang, C.D., Shrager, J.B., et al. (2013). A rare popu-
lation of CD24(+)ITGB4(+)Notch(hi) cells drives tumor propagation in NSCLC
and requires Notch3 for self-renewal. Cancer Cell 24, 59–74.Cancer Cell 26, 33–47, July 14, 2014 ª2014 Elsevier Inc. 47
